Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 3
2019 5
2020 2
2021 1
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.
Adegoke NA, Gide TN, Mao Y, Quek C, Patrick E, Carlino MS, Lo SN, Menzies AM, Pires da Silva I, Vergara IA, Long G, Scolyer RA, Wilmott JS. Adegoke NA, et al. Among authors: gide tn. J Immunother Cancer. 2023 Oct;11(10):e007144. doi: 10.1136/jitc-2023-007144. J Immunother Cancer. 2023. PMID: 37865395 Free PMC article.
Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.
Mao Y, Gide TN, Adegoke NA, Quek C, Maher N, Potter A, Patrick E, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Carlino MS, Lo SN, Menzies AM, da Silva IP, Long GV, Scolyer RA, Wilmott JS. Mao Y, et al. Among authors: gide tn. J Transl Med. 2023 Apr 13;21(1):257. doi: 10.1186/s12967-023-04092-9. J Transl Med. 2023. PMID: 37055772 Free PMC article.
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy.
Lee H, Ferguson AL, Quek C, Vergara IA, Pires daSilva I, Allen R, Gide TN, Conway JW, Koufariotis LT, Hayward NK, Waddell N, Carlino MS, Menzies AM, Saw RPM, Shklovskaya E, Rizos H, Lo S, Scolyer RA, Long GV, Palendira U, Wilmott JS. Lee H, et al. Clin Cancer Res. 2023 Jul 5;29(13):2513-2524. doi: 10.1158/1078-0432.CCR-22-2657. Clin Cancer Res. 2023. PMID: 36790412
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis.
Nahar KJ, Marsh-Wakefield F, Rawson RV, Gide TN, Ferguson AL, Allen R, Quek C, da Silva IP, Tattersal S, Kiely CJ, Sandanayake N, Carlino MS, McCaughan G, Wilmott JS, Scolyer RA, Long GV, Menzies AM, Palendira U. Nahar KJ, et al. Among authors: gide tn. JCI Insight. 2022 Nov 8;7(21):e157839. doi: 10.1172/jci.insight.157839. JCI Insight. 2022. PMID: 36173679 Free PMC article.
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.
Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Hahn AW, et al. Among authors: gide tn. Clin Cancer Res. 2023 Jan 4;29(1):154-164. doi: 10.1158/1078-0432.CCR-22-2661. Clin Cancer Res. 2023. PMID: 36166093 Free PMC article.
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Pires da Silva I. Conway JW, et al. Among authors: gide tn. J Immunother Cancer. 2022 Sep;10(9):e004884. doi: 10.1136/jitc-2022-004884. J Immunother Cancer. 2022. PMID: 36096531 Free PMC article.
Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.
Gide TN, Pires da Silva I, Quek C, Ferguson PM, Batten M, Shang P, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Scolyer RA, Long GV, Wilmott JS. Gide TN, et al. Cancers (Basel). 2021 Jun 25;13(13):3186. doi: 10.3390/cancers13133186. Cancers (Basel). 2021. PMID: 34202352 Free PMC article.
18 results